Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)

• Status: Recruiting
• Trial end date: 2024-02-01

Summary

With this research study has following goals

• To confirm the highest tolerable dose of palbociclib in combination with chemotherapy is safe and well-tolerated.

• To learn more about side effects of palbociclib in combination with chemotherapy;

• To learn more about the biological effects of palbociclib on the cells in your body

• Phase: Phase 1

Details

• Lead Sponsor: Stanford University; Tanja Andrea Gruber
• Treatments: BB 1101; Bortezomib; Dexamethasone; Dexamethasone acetate; Doxorubicin; Liposomal doxorubicin; Palbociclib